Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Clinical evidence

ANX007-GLA-01

26 evidence topics · 4 sources

Objective
Location and study date
Registry dates for the phase 1a study
MilestoneRegistry record
Study start (actual)“2018-03-23”
Primary completion (actual)“2018-08-03”
Study completion (actual)“2018-08-03”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics of the phase 1a study by dose cohort
CharacteristicANX007 1.0 mg (n = 3)ANX007 2.5 mg (n = 3)ANX007 5.0 mg (n = 3)Overall (n = 9)
Age, mean (SD), yr“66.3 (12.5)”View highlighted excerpt for this quote“70.7 (4.0)”View highlighted excerpt for this quote“72.7 (3.5)”View highlighted excerpt for this quote“69.9 (7.4)”View highlighted excerpt for this quote
Age, median (min, max), yr“66.0 (54, 79)”View highlighted excerpt for this quote“73.0 (66, 73)”View highlighted excerpt for this quote“73.0 (69, 76)”View highlighted excerpt for this quote“73.0 (54, 79)”View highlighted excerpt for this quote
Male, n (%)“1 (33.3)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“6 (66.7)”View highlighted excerpt for this quote
Female, n (%)“2 (66.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (33.3)”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote
Black/African American, n (%)“1 (33.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote
Asian, n (%)“0”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote
White, n (%)“2 (66.7)”View highlighted excerpt for this quote“1 (33.3)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“6 (66.7)”View highlighted excerpt for this quote
Weight, mean (SD), kg“105.2 (6.7)”View highlighted excerpt for this quote“83.7 (7.2)”View highlighted excerpt for this quote“82.2 (15.6)”View highlighted excerpt for this quote“90.3 (14.5)”View highlighted excerpt for this quote
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events in the phase 1a study by dose cohort
n (%)ANX007 1 mg (n = 3)ANX007 2.5 mg (n = 3)ANX007 5 mg (n = 3)Overall (n = 9)
Any TEAE“3 (100.0)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“9 (100.0)”View highlighted excerpt for this quote
Ocular disorders“3 (100.0)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“8 (88.9)”View highlighted excerpt for this quote
Infection“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (33.3)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote
Treatment-related TEAE“3 (100.0)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“8 (88.9)”View highlighted excerpt for this quote
Conjunctival hemorrhage“0”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote
Conjunctival hyperemia“3 (100.0)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“8 (88.9)”View highlighted excerpt for this quote
Eye irritation“2 (66.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote
Study limitations
Summary: glaucoma population, small open-label cohorts, and serum-only pharmacodynamics

ANX007-GLA-01 was a first-in-human, open-label, single-dose escalation study in 9 participants with primary open-angle glaucoma (3 per dose cohort of 1.0, 2.5, and 5.0 mg), a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. The study had no masking and no control arm, follow-up lasted 8 weeks, and sample sizes were “determined by clinical and practical, rather than statistical, considerations”, with data presented descriptively. Aqueous humor was not sampled in this study, so pharmacokinetics and target engagement were assessed in serum only, where unbound ANX007 was not detected. The article states that there were no treatment-emergent adverse events after single injections, and in the same paragraph reports 8 ocular treatment-emergent adverse events and 1 systemic event, with all 9 participants (100.0%) having any treatment-emergent adverse event in its Table 2. The 5-mg dose was given in 100 μL, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose.